JP2009531433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531433A5 JP2009531433A5 JP2009502885A JP2009502885A JP2009531433A5 JP 2009531433 A5 JP2009531433 A5 JP 2009531433A5 JP 2009502885 A JP2009502885 A JP 2009502885A JP 2009502885 A JP2009502885 A JP 2009502885A JP 2009531433 A5 JP2009531433 A5 JP 2009531433A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- sequence
- e6ap
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000014509 gene expression Effects 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims 15
- 101100155061 Homo sapiens UBE3A gene Proteins 0.000 claims 12
- 101100155062 Mus musculus Ube3a gene Proteins 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims 2
- 208000037273 Pathologic Processes Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000009054 pathological process Effects 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 208000035657 Abasia Diseases 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050448 human UBE3A Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- ONKSSDKXDIVIHK-UHFFFAOYSA-N n,n-didecyldodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC ONKSSDKXDIVIHK-UHFFFAOYSA-N 0.000 claims 1
- 150000008300 phosphoramidites Chemical class 0.000 claims 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78583706P | 2006-03-24 | 2006-03-24 | |
| US82578206P | 2006-09-15 | 2006-09-15 | |
| PCT/US2007/007241 WO2007111998A2 (en) | 2006-03-24 | 2007-03-23 | Dsrna compositions and methods for treating hpv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531433A JP2009531433A (ja) | 2009-09-03 |
| JP2009531433A5 true JP2009531433A5 (OSRAM) | 2010-05-20 |
Family
ID=38541679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502885A Withdrawn JP2009531433A (ja) | 2006-03-24 | 2007-03-23 | ＨＰＶ感染処置のためのｄｓＲＮＡ組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7956177B2 (OSRAM) |
| EP (1) | EP1999260A2 (OSRAM) |
| JP (1) | JP2009531433A (OSRAM) |
| KR (1) | KR20080106554A (OSRAM) |
| AU (1) | AU2007230995B2 (OSRAM) |
| BR (1) | BRPI0709147A2 (OSRAM) |
| CA (1) | CA2644621A1 (OSRAM) |
| MX (1) | MX2008012173A (OSRAM) |
| RU (1) | RU2008141977A (OSRAM) |
| WO (1) | WO2007111998A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090064A1 (es) * | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| WO2010123365A1 (en) * | 2009-04-24 | 2010-10-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv) |
| AU2009222562A1 (en) * | 2009-10-01 | 2011-04-21 | Peter Maccallum Cancer Institute | Cancer therapy |
| WO2012016139A2 (en) | 2010-07-29 | 2012-02-02 | Sirnaomics, Inc. | Sirna compositions and methods for treatment of hpv and other infections |
| KR101520383B1 (ko) * | 2012-08-02 | 2015-05-15 | 에이비온 주식회사 | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 |
| PL235847B1 (pl) * | 2014-04-11 | 2020-11-02 | Centrum Onkologii Inst Im Marii Sklodowskiej Curie | Zestaw i sposób do wykrywania obecności onkogennych wirusów HPV |
| EP4076471A4 (en) * | 2019-12-18 | 2023-12-27 | National University of Singapore | Method for treating angelman syndrome and related disorders |
| US20240279755A1 (en) * | 2021-06-09 | 2024-08-22 | The Regents Of The University Of Michigan | Materials and methods for measuring hpv ctdna |
| WO2025128853A2 (en) * | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858987A (en) | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| CA2452653A1 (en) | 2001-07-17 | 2003-01-30 | Anne Josephine Milner | Silencing of gene expression by sirna |
| US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| DE10302421A1 (de) | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
| CA2603730A1 (en) * | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| KR101362681B1 (ko) * | 2006-03-31 | 2014-02-13 | 알닐람 파마슈티칼스 인코포레이티드 | Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법 |
| US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
-
2007
- 2007-03-23 KR KR1020087023178A patent/KR20080106554A/ko not_active Ceased
- 2007-03-23 AU AU2007230995A patent/AU2007230995B2/en active Active
- 2007-03-23 MX MX2008012173A patent/MX2008012173A/es active IP Right Grant
- 2007-03-23 CA CA002644621A patent/CA2644621A1/en not_active Abandoned
- 2007-03-23 EP EP07753837A patent/EP1999260A2/en not_active Withdrawn
- 2007-03-23 US US12/294,388 patent/US7956177B2/en active Active
- 2007-03-23 RU RU2008141977/13A patent/RU2008141977A/ru not_active Application Discontinuation
- 2007-03-23 WO PCT/US2007/007241 patent/WO2007111998A2/en not_active Ceased
- 2007-03-23 BR BRPI0709147-8A patent/BRPI0709147A2/pt not_active IP Right Cessation
- 2007-03-23 JP JP2009502885A patent/JP2009531433A/ja not_active Withdrawn
-
2011
- 2011-05-26 US US13/116,947 patent/US20110230546A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531433A5 (OSRAM) | ||
| JP2009513144A5 (OSRAM) | ||
| JP2021006029A5 (OSRAM) | ||
| JP2012511332A5 (OSRAM) | ||
| JP2011505833A5 (OSRAM) | ||
| EP2516647B1 (en) | Molecule for treating an inflammatory disorder | |
| JP2010532163A5 (OSRAM) | ||
| CN103290009B (zh) | 具有促进iNOS mRNA的分解的NO产生抑制活性的正义寡核苷酸以及iNOS产生量的抑制方法 | |
| JP2014527401A5 (OSRAM) | ||
| JP2009536827A5 (OSRAM) | ||
| JP2008523157A5 (OSRAM) | ||
| WO2008109369A4 (en) | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof | |
| JPWO2009044899A1 (ja) | 細胞の増殖を制御する核酸 | |
| JP2012503493A5 (OSRAM) | ||
| CN105907756A (zh) | 延长的dicer酶底物和特异性抑制基因表达的方法 | |
| KR20120047892A (ko) | ｍｉＲＮＡ 억제제 및 유사체를 위한 화학 변형 모티프 | |
| JP2014518612A5 (OSRAM) | ||
| WO2016115490A1 (en) | Compounds and methods for modulation of dux4 | |
| US9145557B2 (en) | Oligonucleotides for modulation of target RNA activity | |
| WO2006032041A3 (en) | Compositions and methods for inhibiting expression of anti-apoptotic genes | |
| WO2008109361B1 (en) | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof | |
| WO2007111998A3 (en) | Dsrna compositions and methods for treating hpv infection | |
| CN114901821A (zh) | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| EP3587577B1 (en) | Asymmetric sirna for inhibiting expression of male pattern hair loss target gene | |
| WO2013065791A1 (ja) | 遺伝子発現抑制用二本鎖核酸分子 |